Re: Farmas USA
HZNP
Resultados:
-- Fourth-Quarter 2017 Net Sales of $274.2 Million;
Fourth-Quarter 2017Net Loss of $46.4 Million; Adjusted EBITDA of $102.7 Million --
-- Fourth-Quarter 2017 Operating Cash Flow of $143.2 Million;
Fourth-Quarter 2017 Non-GAAP Operating Cash Flow of $157.9 Million --
-- Full-Year 2017 Net Sales of $1.056 Billion;
Full-Year 2017 Net Loss of $410.5 Million; Adjusted EBITDA of $389.7 Million --
-- Full-Year 2017 Operating Cash Flow of $280.2 Million;
Full-Year 2017 Non-GAAP Operating Cash Flow of $393.1 Million;
Year-End 2017 Cash Balance of $751.4 Million --
-- Full-Year 2017 Net Sales of Rare Disease Medicines Increased 60 Percent from Full-Year 2016
and Represented 59 Percent of Total 2017 Net Sales --
-- Full-Year 2018 Net Sales Guidance of $1.150 Billion to $1.180 Billion;
Full-Year 2018 Adjusted EBITDA Guidance of $370 Million to $395 Million,
Reflecting Significant Investment in Future Growth Drivers --
Q4 EPS of $0.29 beats by $0.07.
Revenue of $274.22M (-11.6% Y/Y) beats by $9.74M.